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Introduction
Since 2004, access to medical treatment for people living with HIV, including antiretroviral drugs
(ARVs), has seen tremendous growth in Southern countries, through the impetus of the WHO’s
“3 by 5” programme. By the end of 2006, unanimous consensus was reached on the need to expand
therapeutic treatment and prevention, using a complementary and simultaneous approach to limit the
spread and impact of the HIV/AIDS epidemic in countries with limited resources (WHO, 2006).
Research completed with the first cohorts of patients treated with ARVs showed very early on that the
fees for care charged to patients constituted a major obstacle to effective therapeutic treatment
(Whiteside and Lee, 2005; Braitstein et al., 2006). In 2005, this observation led the WHO “to advise
countries to adopt a policy of free access at the point of service delivery for an ‘essential packet’ of
HIV care and treatment, including antiretroviral treatment” (WHO, 2005). Since 2006, the abolition of
user fees at the point of service delivery for care and drugs is one of the pillars of the public health
approach proposed by the WHO, within the framework of universal free access to treatment (Gilks
et al., 2006).
Numerous African countries are involved in free ARV-drug distribution; very few, however, have taken
the plunge in providing complete free medical treatment. Most officials who shape health policies in
Africa have doubts about the feasibility of complete free access, fearing that such a decision will lead
to high costs that will be impossible to bear in the short- or medium-term in relation to the country’s
budget.
Senegal was the first country in Africa to provide ARV drugs free of charge in 2003, as well as HIV
tests, CD4 counts and treatments for several opportunistic infections. Nevertheless, by the end of
2007, treatment is still not completely free because patients must pay for their consultations,
hospitalisation, biological exams and various other drugs. Current debate revolves around expanding
free access to include all components of medical care.
Based on the data from several different studies in Senegal, this chapter aims to assess the economic
feasibility of complete free access to treatment for HIV/AIDS in this country. This evaluation was
conducted in three steps. Firstly, an estimation of patients’ direct costs for treatment was calculated,
using two different methods that were then compared; this estimation enabled us to calculate the
additional costs that must be met by the State to implement complete free access to care for PLWHA
when ARVs are already distributed free of charge in the country. Secondly, we compared the amount
of additional resources needed to provide complete free access with those that were disbursed by the
State for the 2002–2006 period. Finally, we projected costs for the 2007–2011 period to verify whether
a policy of complete free access would be feasible based on pre-allocated funding for this period.
2Background: The epidemiological situation in Senegal
The HIV/AIDS epidemic is highly concentrated in Senegal. Prevalence is low and stable — around
1.5% among pregnant women, 0.7% in the general population, and 15% to 30% among sex workers
and men who have sex with men (Meda et al., 1999; MSPM, 2006). This situation is partly
attributable—with no study to prove it—to the early prevention efforts implemented on the national
level, combined with a bold policy launched in 1998 to provide therapeutic treatment through
antiretroviral drugs within the framework of a government programme, the Senegalese Antiretroviral
Drug Access Initiative (Initiative Sénégalaise d'Accès aux médicaments Antirétroviraux  ISAARV).
From the start of the programme, ARVs were subsidised to make them more readily available to
people with low purchasing power. These subsidies varied between 50% and 95% of the treatment
costs, and a complete subsidy was granted to those who were most destitute or those who met
various social criteria (e.g. PLWHA association members). Several operational studies quickly showed
the negative impact that patient drug payments had on access to care and the quality of medical
follow-up (Laniece et al., 2003; Desclaux et al., 2004). The payment amounts were lowered several
times until December 2003, the date when free access to ARV drugs was announced for all patients
living in the country.
Initially launched in the capital, this programme was gradually expanded throughout the entire country
in 2001. The decentralisation process is still under way; nevertheless, in 2007, 17 hospitals and 32
health centres provided therapeutic and social care for HIV/AIDS throughout the entire national
territory. At the end of 2006, close to 5000 persons benefited from treatment including antiretroviral
drugs.
Screening tests are free in all of the country’s public health structures. ARVs purchased by the State
are provided to patients free of charge, regardless of the therapeutic regimen (first- or second-line).
CD4 counts and treatment for certain opportunistic infections (anti-tuberculosis and oral, genital and
neuro-meningeal antifungal agents; Cotrimoxazole) are also provided for free. The Ministry of Health
also provides various non-specified drugs (antibiotics, anti-inflammatories, iron, etc.), though
sporadically, depending on the supply. However, medical treatment is not completely free since
patients must pay for consultation fees, complementary exams (biological exams [other than CD4
counts] and medical imaging) hospitalisation and any drugs beyond those available (cf. above). In
effect, one must pay for public health services in Senegal, regardless of the level of the health
structure (health centre, regional or national hospital). Only a few diseases (tuberculosis, leprosy) and
medical services (childbirth in some regions of the country) or certain social categories (persons over
the age of 60) guarantee the right to partial or complete coverage for the cost of care.
Methods
The evaluation is based on the estimated direct cost of medical care for PLWHA; this estimate was
calculated using two different methods. The individual costs, reported for the total number of patients
requiring medical care, enabled us to estimate the difference between funding needs and the
resources available to the State. A cost projection was then conducted, based on national
epidemiological data used to plan for the resources needed in the coming years. The two calculation
methods have been detailed below.
• Calculation of individual direct costs for medical treatment
Costs were calculated first for patients who received ARV treatment and then for patients whose
immune status did not yet require ARVs.
- For patients receiving ARV treatment: the direct costs of medical care are comprised of the costs of
medical treatment (antiretroviral drugs and drugs for opportunistic infections), various complementary
exams necessary for diagnosis and monitoring treatment (medical imaging, biological exams [chest X-
ray, ASAT/ALAT, blood count, glucosemia, HBV-HCB serology, tuberculin test and creatine]),
hospitalisation costs and fees for consultations.
- For patients not receiving ARV treatment: the direct cost was calculated based on the protocol
defined by the national recommendations, which stipulates that a medical consultation, a full blood
count and a CD4 count are conducted every six months.
3- Travel costs have not been taken into account in this study, although they can clearly have a major
influence on the access to care.
The direct costs of treatment were calculated using two different methods:
1) By calculating total expenses over a period of 22 months (July 2003 to April 2005) from a sample of
299 adult patients treated by triple therapy (2 NRTI + 1 PI or NNRTI) for a median duration of 48
months (IQR [interquartile ranges]: 40–62), CD4 > 200 for 80% of patients who were from the ANRS
1290 cohort (see Box 1). This involves the calculated real costs from reimbursements for expenses
covered by patients, added to expenses directly covered by the research programme
The ANRS 1290 cohort
This cohort is composed of the first 420 patients who were treated within the framework of the ISAARV
programme. These people, infected by HIV-1, began their treatment between August 1998 and April
2002. They received follow-up every two months at the ISAARV programme’s first four clinical sites in
Dakar: the Infectious Diseases Unit and the Ambulatory Treatment Centre of Fann Teaching Hospital,
and two Internal Medicine Units at Principal Hospital in Dakar. Follow-up for these patients aimed to
evaluate efficacy, tolerance, adherence and the emergence of resistances to antiretroviral drugs, as
well as the social impact of treatment over the long term (Etard et al., 2006). This is one of the earliest
cohorts of patients treated by ARVs in Africa. Various biological and clinical exams are conducted
every two months; these patients benefit from support measures for adherence that were implemented
within the framework of ISAARV (association support, participation in discussion groups and social
services support). All health expenses incurred by patients were reimbursed to them if they were
linked to HIV infection, whether for the prescriber, the point of service delivery or the purchase of
drugs, upon production of a receipt. Compensation for travelling costs was provided to people who
faced transport difficulties. Precise accounting was kept on each patient’s expenses.
- 2) By evaluating the theoretical costs needed to apply national treatment protocols that have been
developed on the basis of the WHO guidelines (MSPM, 2005). These protocols define treatment
modalities for patients (minimal frequency of medical consultations), which complementary exams to
conduct and which therapeutic regimens to follow for ARV drugs and for principle opportunistic
infections. The costs have been calculated based on current fees charged at the Fann Hospital
(treatment reference centre), the price of ARV drugs available in Senegal (prices from the 2003
invitation to tender) and from the National Supply Pharmacy catalogue for 2005–2006 for other drugs.
The amount has been estimated using an event’s frequency of occurrence and the unit cost applied to
this event.
The different expenditures have been divided into two categories:
- The “basic package” is made up of all services that are already provided for free by the State; these
include antiretroviral drugs, CD4 counts, and some treatments for opportunistic infections (anti-
tuberculosis and oral, genital and neuro-meningeal antifungal agents; Cotrimoxazole).
- The “complementary package” includes all other medical procedures that are essential to medical
treatment but which are currently paid for by patients. This packet comprises medical consultation
fees, biological follow-up exams (ASAT/ALAT, blood count, glucosemia, HBV-HCB serology,
tuberculin test and creatine) and medical imaging (chest X-ray), hospitalisations and drugs for
opportunistic infections that are not covered by the State (for example, acyclovir for herpes virus
infections, ganciclovir for CMV infections, bleomycine + vincristine for Kaposi’s sarcoma, etc.).
• The feasibility of expanding universal free access was assessed using an analysis of the
2002–2006 National Strategic Plan budget, based on information provided by the Ministry of Health.
• The projection for costs for the 2007–2011 period is based on the estimated demand for
treatment, calculated from information provided by the Ministry of Health (MSPM, 2006) (see Table 1),
in which we have applied the unit costs defined by our study.
In 2006, it was assumed that 5000 persons were treated with ARVs. Need for ARV treatment [b] has
been estimated using the standard hypothesis that 20% of seropositive persons will require ARV
treatment. The growth in the number of patients who are treated [c] is based on an increase of 20%
during the year 2007, then 15% for the following years.
4Year Total
PLWHA
[a]
Need for
ARV
treatment
[b]
No. of
persons
receiving
ARV
treatment
[c]
% of
ARV treatment
coverage/need
[d=c/b]
No. of
identified
PLWHA who
do not need
ARV
treatment [e]
Total no.
of PLWHA
who
receive
care
[f=c+e]
% of medical
coverage/demand
[g=f/a]
2007 56,310 11,262 6000 53 6000 12,000 21
2008 58,440 11,688 6900 59 6900 13,800 24
2009 59,810 11,962 7900 66 7900 15,800 26
2010 61,720 12,344 10,500 85 10,500 21,000 34
2011 63,864 12,773 11,700 92 11,700 23,400 37
Table 1: Estimation of the number of seropositive persons and demand for medical treatment for the
years 2007 to 2011 (National Strategic Plan, 2007–2011)
For the years 2007 to 2011, the number of persons receiving ARV treatments [c] and the number of
PLWHA who have been identified but do not need ARV treatment yet [e] have been estimated based
on statements provided by the Ministry of Health’s Division for the Fight Against STI/HIV/AIDS in 2006.
This growth is realistic when considering increased capacity due to the decentralisation process and
expanded testing.
The estimated number of persons treated by ARVs for the years 2007 to 2011 may be over-estimated,
since the proposed amounts would lead to a coverage rate for demand [d] close to 92%. Even though
it may seem excessive, this amount was used insofar as it provides a maximum estimation for
potential costs.
In 2006, testing still only involved a limited number of persons and was often carried out when a
clinical picture suggested HIV infection, and was therefore overdue in terms of the disease’s evolution.
The number of identified seropositive persons who did not yet need ARV treatment was estimated at
5000 persons in 2006, or equal to the number of patients who were treated. For the period
2007–2011, we have estimated that the number of persons diagnosed as seropositive, but not
needing treatment yet [e], will correspond to the number of patients treated by ARVs. This hypothesis
will lead to increased testing, thus reaching 37% of seropositive persons in 2011 [g]; this estimate is
quite realistic.
Results and Findings
First, we present the estimates for direct costs of care for PLWHA, based on the two different
calculation methods described above. In addition, a distinction was made between the situations
involving patients who receive ARV treatment and those involving patients who do not because their
physical status does not yet require it. Since the price of ARV drugs represents a large proportion of
the cost of care, and since these prices fell significantly during the period 2003–2006, we have
reported relevant information concerning changes in these prices. This has been taken into
consideration in calculating the overall cost of care. The second part then presents an analysis of the
national budget for the fight against AIDS for the 2002–2006 period, in order to estimate the budgetary
margin for manoeuvre for health authorities. Finally, in the third part, we propose a projection for
expenditures that would be incurred by a decision to provide universal free access for the 2007–2011
period.
5Direct Costs
• Patients treated with ARV drugs
Table 2, below, presents estimates obtained through two calculation methods. Column A has been
obtained from national recommendations for treatment and column B from real expenses incurred for
patients in the ANRS 1290 cohort.
 
A
Estimation based on
national
recommendations [1]
B
ANRS 1290
cohort survey
Basic package [4] Costs: €/patient/month
%of
total
cost (A)
Costs:
€/patient/month
% of
total
cost (B)
ARVs [3] 48 [2] 97% 68.4 98%
CD4 [3] 1.2 2% 1.7 2%
Drugs [4] 0.6 1% – 0%
Subtotal 49.8 90% 70.1 89%
Complementary Package [5]
Biological package [6] 2.1 39% 5.1 58%
Consultations 0.8 14% 0.8 9%
Hospitalisation [7] 0.5 8% 0.5 5%
Other complementary exams – 0% 1.2 14%
Drugs for opportunistic infections 2.1 39% 1.2 14%
Subtotal 5.5 10% 8.8 11%
TOTAL 55.3 78.9
Table 2: Average monthly direct costs of medical care per patient.
Notes:
[1] - Therapeutic treatment guide for people living with HIV, Ministry of Health, Hygiene and
Prevention, April 2005.
[2] - Weighted mean of the most frequently-used therapeutic protocols in Senegal; cost calculation
based on the price list from the National Supply Pharmacy’s 2003 invitation to tender.
[3] - Currently provided by the State.
[4] - Some treatments for opportunistic infections are provided free of charge by the State (e.g.
treatment for tuberculosis).
[5] - The complementary package amount has been estimated using the frequency of the outbreak of
an event and the unit cost involved with this event. For the ANRS cohort patients, these are costs
calculated from patients’ reimbursed expenses, added to expenses directly covered by the research
programme (e.g. biological package).
[6] - This lump sum includes: chest X-ray, ASAT/ALAT, blood count, glucosemia, HBV-HCB serology,
tuberculin test and creatine.
[7] - Hospitalisation costs have been estimated on the basis of fees charged in public structures.
The two methods used here (protocol-based vs. patient sample) converge toward comparable values
for costs. The total monthly cost per patient lies between 55€ and 80€ (or 660€ to 960€/year), using
the 2003 ARV drug price list. The highest amount for patients from the ANRS cohort includes the use
of some second-generation ARVs (tenofovir, lopinavir + ritonavir) that are more expensive and a more
complete biological follow-up (bilirubinemia, cholesterolemia, triglyceride and prothrombin time).
The basic package that is already covered by the State (ARVs, CD4 counts and treatments for a few
opportunistic infections) covers 90% of the total cost. The cost of the complementary package per
patient varies between 5.5€ and 8.8€ per month (or 66€ to 106€/year); it therefore accounts for
approximately 10% of the total cost; half of these expenses are for biological exams.
6• Patients who do not need ARV treatment
The annual direct cost of medical follow-up for an HIV+ person whose clinical-immune status does not
justify treatment with ARV drugs is estimated at 39€ (based on a medical consultation, a full blood
count and a CD4 count every six months)
• Evolution of ARV treatment costs
The price of ARV drugs has undergone several reductions since the programme’s inception in 1998,
with the greatest decreases occurring between 2000 and 2003. Nevertheless, significant price
decreases continued until 2006, allowing for a reduction of between 18% and 63% depending on the
therapeutic protocol (Table 3).
Therapeutic combination
2003 prices
€/month
2006 prices
€/month
Frequency
of use [1]
2003 weighted
mean €/month
2006 weighted
mean €/month
AZT+3TC+EFZ 62.24 34.08 48% 29.87 16.36
AZT+3TC+NVP 29.49 18.18 16% 4.72 2.91
AZT+3TC+IDV 32.85 26.95 16% 5.26 4.31
D4T+3TC+NVP 21.61 10.24 8% 1.73 0.82
D4T+3TC+EFZ 54.36 26.14 8% 4.35 2.09
D4T+3TC+IDV 51.86 19.01 4% 2.07 0.76
 100% 48.00 27.25
Table 3: Price of the six most frequently used therapeutic combinations in Senegal, based on 2003
and 2006 supply prices and monthly weighted mean for treatment.
Note:
[1]: Frequency of use in the national programme.
The weighted mean of the six most frequently-used therapeutic protocols in the national programme is
27.25€ at 2006 prices. This brings the cost of the “basic package” down to 28.97€/month, and the
overall cost of complete care to approximately 34.30€/month (412€/year) with 84% of this cost
dependent on the price of ARV drugs and reagents for CD4 counts.
• 2002–2006 budget for the fight against AIDS in Senegal
To assess the feasibility of extending free access, we have compared the necessary additional
resources with those that are currently mobilised.
In 2001, a strategic plan was developed to organise funding for the entire fight against HIV/AIDS
(CNLS, 2001). A total amount of 92.69 Million€ (M€) was projected over a five-year period. In
response to the ambitious goal concerning the number of patients to be treated (7,000 patients in
2006), considerable budget increases were planned to purchase ARV drugs (Vinard et al., 2003). The
budget allocated to ARVs should increase from 1.22M€ to 7.31M€, and the budget for reagents should
double in five years to reach 69,000€. Budgets for opportunistic infections were estimated for an
annual amount which increased from 125,000€ to 183,000€. According to these projections, the whole
programme should have seen less spectacular progress, but nevertheless went from 16.7M€ to nearly
23M€ per year.
In the end, this programme was not fully funded; however, nearly 80.8M€ (or over 87%) had been
promised by the State and various donors, attesting to the Senegalese programme’s success. During
the first three years (2002–2004), 34.56M€ — accounting for approximately half of the expenditure —
had been implemented. Due to a significant increase in projected expenditures for 2005 and 2006, the
outstanding balance could only be relatively modest (under 4%).
During the period 2002–2006 (see Table 4), the budget allocated to medical care for PLWHA
increased from 1.98M€ to 2.36M€; at the same time, the total health budget rose from 61.43M€ to
116.16M€. The budget for medical care for PLWHA accounted for 3.2% of the health budget in 2002
and then stabilised at about 2% in the following years (2003 to 2006).
7Millions of € 2002 2003 2004 2005 2006
Public Health Expenditure (Ministry of Health,
Hygiene and Prevention Budget - operations and investment)
61.43 68.23 91.31 71.57 116.16
Medical Care of PLWHA
(ARVs + OI + reagents)
1.98 1.73 1.7 2.32 2.36
Medical Care of PLWHA
/Public Health Expenditure
3.2% 2.5% 1.9% 2.1% 2%
Table 4: Ministry of Health, Hygiene and Prevention budget (operations, investment) and projected
budget for the purchase of ARVs, drugs for opportunistic infections and CD4 reagents over the period
from 2002–2006 (source: Multisectorial Plan and Law of Finances, Senegal).
Over the period from 2002–2006, funding for drugs was primarily provided by the Senegalese State
(Ministry of Health) (see Table 5), underscoring the national effort in AIDS care. International donors
only intervened occasionally (2004 and 2005) in this domain; their interventions concentrated on other
forms of support.
Millions of € 2002 2003 2004 2005 2006
Ministry of Health 1.98 1.73 0.105 2.16 2.36
Global Fund - - 275 0.15 -
World Bank - - 776 - -
Total 1.98 1.73 1.7 2.32 2.36
Amount delivered
(% delivered/projected)
0.75
(37%)
0.95
(54%)
1.32
(77%)
1.57
(67%)
nda
Table 5: Source of funding for ARVs, drugs for opportunistic infections and CD4 reagents, and actual
amounts delivered, years 2002–2006.
The actual amounts of drugs and reagents delivered could be calculated using documentation from
the National Supply Pharmacy, which handles the importation of all drugs and reagents for the
national programme. During this 2002–2006 period, the amounts delivered appeared to be much
lower than the funding obtained; at best, the amount delivered in 2004 corresponded to 77% of the
budget obtained. This means that the State did not commit the entire available budget to purchasing
ARV drugs and reagents during the period in question. One the one hand, this is due to the fact that
the price of ARVs dropped significantly during this period, hence making it possible to obtain the
necessary drug quantities at a low cost. On the other hand, however, it is also due to flaws in drug and
reagent supply (lapses in stock management, undelivered orders) that led to brief and frequent supply
breaks. Therefore, it had been possible to commit between 0.38M€ and 1.23M€ to supplementary
expenditures, depending on the year. The budgets initially projected for patient treatment could have
easily covered totally free care during the period from 2002–2006.
Medium-term projection (2007–2011)
• Assessment of the cost of complete free access
Using the estimation for demand furnished by the Ministry of Health, to which we have applied the
previously calculated direct costs (basic package at 346€/PPY, and complementary package at
66€/PPY, total cost of 412€/PPY), we have calculated the changes in cost for the basic package
already provided by the State [a], the complementary package [b] and the cost of medical follow-up for
PLWHA not needing ARV treatment [c] based on assessments of previously-charged unit costs and
on the price of drugs obtained from the 2006 invitation to tender (see Table 6).
8Year
Cost of
“basic package” for
PLWHA on HAART
M€ [a]
Cost of
“complementary package”1
of care for PLWHA on HAART
M€ [b]
Cost of
care for PLWHA
not needing HAART
M€ [c]
Total
M€ [d]
2007 2.09 0.39 0.23 2.70
2008 2.40 0.45 0.27 3.11
2009 2.75 0.51 0.30 3.56
2010 3.65 0.68 0.41 4.73
2011 4.07 0.75 0.45 5.27
Table 6: Estimation of the cost of medical care for PLWHA, 2007–2011.
The cost of the complementary package for patients on ARVs [b] would be 0.39M€ in 2007; in 2011, it
would reach 0.75M€; the cost of medical follow-up for PLWHA who do not need ARV treatment [c]
would increase from 0.23M€ to 0.45M€. Therefore, complete free access would require a
supplementary cost of 1.2M€ in 2011 [b+c], this amount comprising 22% of the total amount.
• Placing complete free access in the 2007–2011 budgetary estimates
Medical and social care for PLWHA (including orphaned children and victims of AIDS) accounts for
42% of the total amount of the planned budget in the 2007–2011 National Strategic Plan.
The annual distribution of the planned budget for care relative to the total budget is illustrated in the
following figure (Figure 1). It confirms that the cost of complete free access to care is fully covered by
the planned budgets. The decision to expand free access to cover all care for all PLWHA would
therefore not require any reallocation of the initially-estimated resources.
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Figure 1: Total budget for the National Strategic Plan, estimated budget of the care component and
cost estimations for complete care, 2007 to 2011.
                                                
1 - As defined above, namely: medical consultation fees, biological follow-up exams (ASAT/ALAT,
blood count, glucosemia, HBV-HCB serology, tuberculin test and creatine) and medical imaging (chest
X-ray), hospitalisation and drugs for opportunistic infections that are not covered by the State.
9Discussion
This study may elicit extensive commentary because it extrapolates from an estimate of individual
costs to an analysis of the national programme’s overall funding and its execution. We have limited
ourselves to a brief discussion of the validity of the estimations followed by an effort to place the
expenses generated by complete free access in perspective relative to the programme budget and to
individuals’ resources. Finally, we address the issue of defining the stakes surrounding such a public
health decision.
In many respects, patients in the ANRS 1290 cohort are not representative of the population of
PLWHA receiving ARV treatments in Senegal. Within the framework of the research programme, they
benefit from medical follow-up that is regular, standardised and much better than what is usually
offered in medical consultations in the rest of the health system. No economic barrier ever arises to
limit their medical consumption, since they are reimbursed for all of their health expenses. It might be
assumed that this favourable context increases the demand for care and therefore leads to
overestimated costs, but on the contrary, this easy access has probably allowed for earlier diagnoses
for some opportunistic infections, leading to reduced treatment costs. On the other hand, it has been
demonstrated that during the first 12 months of treatment, morbidity, mortality and consequently the
costs of care are at their highest (Canestri et al., 2004; Etard et al., 2006). Furthermore, these patients
have received medical care for a long time (median duration of ARV treatment of 48 months [IQR
40–62]); the period during which we have calculated the costs (July 2003 to April 2005) corresponds to
a minimum duration of 16 months (maximum of 61 months). The clinical status for most of these
patients is stabilised, which limits their health expenditures. It is expected that over the long term,
costs for care will rise again with the need to move to a new — and more expensive — generation of
therapeutic protocols or even due to undesirable long-term effects of ARVs. These hypotheses could
not be confirmed by our study. Nevertheless, the two methods used here (based on real consumption
by a sample of people and based on a protocol) furnish similar values for costs. Finally, these amounts
are comparable to those calculated in other studies in Senegal (Canestri et al., 2004) and in Côte
d’Ivoire (Laguide et al., 2003).
In 2006 in Senegal, the total cost of medical care for a person on ARV therapy lies around 412€ per
year; 84% of this cost covers the price of ARVs and reagents for CD4 counts. All other necessary care
components account for 16% of costs, divided between biological exams and treatment of
opportunistic infections. The total annual cost of medical care for a PLWHA who does not need ARV
drugs is approximately 40€ per year, with 90% of this amount paying for biological exams. The
Senegalese State, having declared free access to ARV drugs and CD4 counts, therefore covers 84%
of the costs charged to patients. This decision has had a major impact on the programme’s
accessibility for the entire population. Costs that currently remain under the responsibility of patients
(from 67€ to 95€ per year, or less than 8€ per patient per month) may hardly seem high, and even
negligible. However, to understand the impact that this amount could have on patients, it must be seen
relative to their resources. In the region of Dakar, 60% of the population has no fixed employment or
regular revenue. In 2000, 60% of the people lived on less than 23€ per person per month to cover all
of their needs (housing, clothing, food, health, education); moreover, 83% have no social protection
system that allows reimbursement of health expenses (Gomes 2000). Both in their opinion and in that
of the health professionals who provide their care, the costs incurred by patients constitute a major
obstacle to medical follow-up for those who require ARV treatment. Since medical costs for care
mainly cover ARV drugs and laboratory exams, any variation in the price of these drugs and reagents
on the international market will consequently have a major effect on treatment budgets. Therefore it is
essential to maintain and develop national and international initiatives to guarantee access to
preferential pricing for these products in Southern countries.
Analysis of mobilisation of the 2002–2006 Strategic Plan shows that the initially-projected budget for
purchasing ARVs, reagents and drugs for opportunistic infections, calculated to ensure care for 7000
patients in 2006, was fully sufficient. On the other hand, the allocations that were ultimately delivered
correspond to 2002 and 2003 needs and have stagnated in 2004 and 2005, and thus become
markedly lower than the programme’s needs. This translated into several brief interruptions in the
supply of ARV drugs and reagents in 2004, which has slowed down the number of new patients
treated. These difficulties have been due to various administrative dysfunctions within the Ministry of
Health (particularly concerning signing procedures for international markets). In order to treat the
predicted number of patients, the actual planned budget must be mobilised, and the greatest attention
should be given to logistical and organisational aspects.
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The 2007–2011 budgetary estimates signal efforts to maintain financial commitments to controlling the
epidemic in the country. The experience of the 2002–2006 period shows that the major issue at the
national level in terms of public health will be to promote access to care for PLWHA who require
treatment with ARV drugs. Therefore the main challenge facing the State focuses less on the financial
burden of extending the treatment package than it does on increasing the number of persons who are
covered. This need itself depends heavily on the success of the testing policy.
Conclusion
The need for totally free medical care for PLWHA no longer needs demonstration. Funding this care
allows reflection about conditions for a possible expansion in the domain of free access and
contributes in a practical way to clarifying the often dogmatic debate between “payment” and “free
access.”
The analysis of the budgets implemented over 2002–2006 shows that while still maintaining the
funding plan’s initial balance, it would have been possible to free up enough supplementary funding to
deal with all health expenses for PLWHA. Similarly, in terms of assessing needs for future years, it
appears that the supplementary costs brought about by complete free access could be easily covered
without disrupting the 2007–2011 funding plan. Hence, universal free access is budgetarily feasible.
What remains to be defined is how this decision can be integrated into the current health system
without creating disturbances that render it ineffective. Using the results presented in this chapter, a
feasibility study was conducted to explore the various modalities that would allow for implementation of
a national decision announcing complete free access to care for PLWHA. Its main results are
discussed in chapter 14 of this book.
Interest in implementing complete free access can now be envisaged with respect to the expected
benefits in terms of adherence and treatment quality, strengthening the health-care system and the
political message linked to such a decision. Expanding free access can in effect create an opportunity
to better streamline the consumption of drugs for opportunistic infections and associated treatments. In
practice, this consumption, paid for by patients themselves (in public as well as private structures),
rarely corresponds to optimum therapeutic protocols. Moreover, while therapeutic strategies for ARVs
try to simplify protocols to reduce the number of pill intakes per day, with the aim of to improving
treatment adherence, it appears that alternative or unproven treatments — which are often very
expensive — are frequently prescribed. Significant savings can be obtained. It would be paradoxical to
continue expending considerable effort (often with success) to reduce the constraints and costs of
ARV protocols while neglecting the economic constraints associated with treatments for opportunistic
infections.
Implementation of free access to care must be accompanied by the strengthening of health structures.
It is obviously out of the question to ask health structures to carry this burden alone. This
strengthening could take the form of budgetary support or the provision of equipment, drugs or staff to
help improve the services delivered by these structures to the entire community.
From a global perspective, Senegal’s experience in funding medical care for HIV/AIDS is noteworthy
within the international debate about the prospects for free medical services (Nabyonga et al., 2005;
McIntyre et al., 2006; Meessen et al., 2006). This debate is also a pathway to reflection on how to re-
establish public funding. Once again, the fight against HIV/AIDS has played a critical role in revealing
a problem that is felt within all health structures.
They authors thank the Agence Nationale de Recherche contre le Sida (ANRS) for a research grant.
They also wish to thank anonymous referees of this paper for helpful comments.
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